Provided by Healio
CME
Author(s)/Faculty: Michael W. Fried, MD
Source: Healio - Gastroenterology Education Lab
Type:
Articles/Items: 2
Release Date: 9/13/2013
Expiration Date: 9/12/2014
Credit Type: CME
Number of Credit(s): 0.25
Cost: Free
Provider: 
Chronic hepatitis C virus (HCV) infection is a leading cause of cirrhosis, end-stage liver disease, hepatocellular carcinoma, and death from liver disease in the United States. The discovery, development, and availability of direct-acting antiviral agents (DAAs) offers new treatment options and the possibility of improved outcomes for newly diagnosed patients as well as those who have experienced a relapse or failed to respond to previous treatment. However, use of the first generation protease inhibitors introduced new challenges and added to the complexity of HCV treatment and care. With rapid advancements in the field and new agents offering potential improvements in outcomes, shorter treatment durations, use without interferon, and unique adverse event profiles, clinicians must stay informed of the evolving data in order to counsel patients appropriately—in particular, those who may wish to discuss the benefits and risks of initiating therapy now vs. waiting for therapies in the near-term vs, delaying treatment for interferon-free options.
Effective management of HCV continues to pose a challenge for health care practitioners. This activity is a pre-study module corresponding with the topics offered as part of the for the HCV VOICE Meeting Series. The purpose of the unique HCV VOICE initiative is to provide specific, targeted educational opportunities for clinicians who are involved in the management of patients with HCV.
This activity is supported by educational grants from abbvie and Genentech.
Sponsorship Statement: This continuing medical education activity is co-sponsored by 
No comments:
Post a Comment